Skip to main content

Table 1 Baseline clinical and angiographic characteristics of patients in ACS and CCS groups

From: Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study

Characteristics

All (n = 320)

ACS (n = 139)

CCS (n = 181)

P value

Male, n (%)

249 (77.8%)

121 (87.1%)

128 (70.7%)

 < 0.001

Age, years, mean ± SD

59.70 ± 10.45

58.99 ± 11.88

60.25 ± 9.21

0.283

Medical history, n (%)

 Atrial fibrillation

11 (3.4%)

10 (7.2%)

1 (0.6%)

0.001

 Hypertension

166 (51.9%)

79 (56.8%)

87 (48.1%)

0.120

 Diabetes mellitus

80 (25.0%)

32 (23.0%)

48 (26.5%)

0.474

 ASCVD

148 (46.3%)

60 (43.2%)

88 (48.6%)

0.332

 Prior PCI

65 (20.3%)

30 (21.6%)

35 (19.3%)

0.621

 Stroke

19 (5.9%)

10 (7.2%)

9 (5.0%)

0.404

 Alcohol drinking

50 (15.6%)

28 (20.1%)

22 (12.2%)

0.051

Smoking

141 (44.1%)

71 (51.1%)

70 (38.7%)

0.027

 Smoking years

12.90 ± 15.94

15.14 ± 16.36

11.17 ± 15.43

0.027

Laboratory results, mean ± SD

 WBC, × 109/L

7.00 ± 2.36

7.89 ± 2.84

6.32 ± 1.63

 < 0.001

 Hb, g/L

140.76 ± 17.51

138.63 ± 19.88

142.39 ± 15.30

0.057

 HbA1c, %

6.48 ± 1.70

6.43 ± 1.76

6.52 ± 1.65

0.671

 NT-proBNP, pg/ml

670.25 ± 1906.92

1345.28 ± 2727.79

147.76 ± 296.54

 < 0.001

 Hs-cTnI, pg/ml

292.11 ± 978.31

631.49 ± 1376.67

7.93 ± 2.82

 < 0.001

 CK-MB, U/L

25.74 ± 35.65

37.86 ± 44.50

16.40 ± 23.04

 < 0.001

 Glucose, mmol/L

6.15 ± 2.40

6.39 ± 2.91

5.98 ± 1.99

0.266

 Creatine, μmol/L

77.10 ± 80.41

91.36 ± 119.68

66.15 ± 14.16

0.005

 eGFR, ml/min/1.73m2

104.43 ± 28.09

102.07 ± 33.01

106.24 ± 23.57

0.188

 Uric acid, μmol/L

312.55 ± 80.69

332.93 ± 83.66

297.46 ± 75.18

 < 0.001

 TC, mmol/L

3.79 ± 0.99

3.95 ± 1.01

3.68 ± 0.95

0.016

 TG, mmol/L

1.71 ± 1.35

1.85 ± 1.55

1.61 ± 1.17

0.116

 HDL-C, mmol/L

1.06 ± 0.26

1.02 ± 0.24

1.08 ± 0.26

0.023

 LDL-C, mmol/L

2.23 ± 0.84

2.42 ± 0.87

2.09 ± 0.80

 < 0.001

 VLDL-C, mmol/L

0.52 ± 0.47

0.53 ± 0.51

0.51 ± 0.45

0.663

 Apo A1, g/L

1.25 ± 0.26

1.20 ± 0.23

1.29 ± 0.27

0.001

 Apo B, g/L

0.84 ± 0.25

0.89 ± 0.27

0.81 ± 0.23

0.003

 Apo B/A1

0.70 ± 0.25

0.77 ± 0.28

0.64 ± 0.22

 < 0.001

 Lipoprotein (a), mg/dl

23.24 ± 28.42

25.05 ± 28.99

21.84 ± 27.98

0.319

 TSH, μIU/ml

3.51 ± 5.12

3.25 ± 5.09

3.71 ± 5.15

0.439

 D-dimer, μg/ml

564.49 ± 1354.78

749.41 ± 1765.73

422.49 ± 903.22

0.032

 LVEF, %

62.82 ± 7.81

60.77 ± 7.76

64.50 ± 7.46

 < 0.001

Culprit vessels, n (%)

 LAD

191 (59.7%)

70 (50.4%)

121 (66.9%)

 

 LCX

40 (12.5%)

20 (14.4%)

20 (11.0%)

 

 RCA

56 (17.5%)

32 (23.0%)

24 (13.3%)

 

Lesion site, n (%)

 Proximal

165 (51.6%)

72 (51.8%)

93 (51.4%)

 

 Middle

109 (34.1%)

41 (29.5%)

68 (37.6%)

 

 Distal

13 (4.1%)

9 (6.5%)

4 (2.2%)

 

Stents, n (%)

 0

95 (29.7%)

28 (20.1%)

67 (37.0%)

 

 1

124 (38.8%)

55 (39.6%)

69 (38.1%)

 

 2

67 (20.9%)

30 (21.6%)

37 (20.4%)

 

 3

21 (6.6%)

16 (11.5%)

5 (2.8%)

 

  > 3

13 (4.1%)

10 (7.2%)

3 (1.7%)

 

Statins, n (%)

208 (65.0%)

93 (66.9%)

115 (63.5%)

0.531

  1. ACS acute coronary syndrome, CCS chronic coronary syndrome, ASCVD atherosclerotic cardiovascular disease, PCI percutaneous coronary intervention, SD standard deviation, WBC white blood cell, Hb hemoglobin, HbA1c glycosylated hemoglobin, NT-proBNP N-terminal B-type natriuretic peptide, Hs-cTnI high-sensitivity cardiac troponin I, CK-MB creatine kinase-MB, eGFR estimated glomerular filtration rate, TC total cholesterol, TG total triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol, Apo apolipoprotein, TSH thyroid stimulating hormone, LVEF left ventricular ejection fraction, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery